<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541058</url>
  </required_header>
  <id_info>
    <org_study_id>AD202</org_study_id>
    <nct_id>NCT02541058</nct_id>
  </id_info>
  <brief_title>Non-Invasive Chromosomal Evaluation of 22q11.2</brief_title>
  <acronym>22Q</acronym>
  <official_title>Non-Invasive Chromosomal Evaluation of 22q11.2 Using Cell-free Fetal DNA From Maternal Plasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roche Sequencing Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roche Sequencing Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to develop and evaluate a cell-free fetal DNA test (Ariosa
      Test) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.
      Investigators will be evaluating subjects with abnormal U/S.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of Ariosa 22q.11.2 deletion/duplication assay in prenatal patients</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>DiGeorge Syndrome, Velocardiofacial Syndrome, 22q.11.2 Deletion Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients without confirmed 22q.11.2 deletion/duplication</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with confirmed 22q.11.2 deletion/duplication</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Retained samples included extracted DNA and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women carrying a fetus at risk or a confirmed fetus with 22q11.2
        deletion/duplication. A person confirmed to have 22q11.2 deletion/duplication or a
        biologically related parent of a child that has chromosomal deletion/duplication in the
        region of 22q11.2.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is â‰¥18 years of age and able to provide consent or, if under the age of 18,
             the patient has parental consent and child assent provided as required by the
             governing ethics committee.

          2. If pregnant, patients must have a singleton pregnancy and be at least 10 weeks
             gestation at the time of the study blood draw.

          3. Patients must meet at least one of the following conditions at the time of enrollment:

               1. are pregnant with abnormal fetal cardiac findings on ultrasound and is undergoing
                  evaluation with prenatal genetic testing or planned post-natal genetic testing in
                  the immediate newborn period;

               2. are pregnant with fetal ultrasound findings consistent with a 22q11.2
                  deletion/duplication phenotype and is undergoing evaluation with prenatal genetic
                  testing or planned post-natal genetic testing in the immediate newborn period;

               3. are pregnant with a fetus known to have a 22q11.2 deletion/duplication confirmed
                  by genetic testing with documentation is available;

               4. are biologically related parent of an enrolled child has chromosomal
                  deletion/duplication in the region of 22q11.2;

          4. If the site is selected to enroll control patients, they must be pregnant women
             undergoing prenatal genetic evaluation for 22q11.2 deletion/duplication.

        Exclusion Criteria

        Patients meeting any of the following criteria will be excluded from the study:

        1. Patient has history of malignancy treated with chemotherapy and/or major surgery, or
        bone marrow transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Musci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Roche Sequencing Solutions</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Romielle Aquino</last_name>
    <phone>408-209-9098</phone>
    <email>romielle.aquino@roche.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Desiree Hollemon, MSN, MPH</last_name>
    <phone>503-686-8972</phone>
    <email>Desiree.Hollemon@roche.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Fetal Medicine Foundation Belgium</name>
      <address>
        <city>Brussles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Jani, MD</last_name>
      <phone>0032 2 477 3631</phone>
      <email>Jacques.Jani@chu-brugmann.be</email>
    </contact>
    <contact_backup>
      <last_name>Elisa Bevilacqua, MD</last_name>
      <phone>0032 2 477 3631</phone>
      <email>elisa.bevilacqua@chubrugmann.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques Jani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Velocardiofacial Syndrome</keyword>
  <keyword>Shprintzen Syndrome</keyword>
  <keyword>Conotruncal Defects</keyword>
  <keyword>Chromosomal Abnormalities</keyword>
  <keyword>22q, 22q.11.2</keyword>
  <keyword>deletion</keyword>
  <keyword>duplication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>DiGeorge Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

